HWL

HUTCHMED is an innovative, commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has successfully brought several internally discovered drugs to market in China, including fruquintinib, surufatinib, and savolitinib, and is expanding its global footprint through strategic partnerships and international clinical trials. With a robust pipeline of small molecule inhibitors targeting various tyrosine kinases and other oncogenic pathways, HUTCHMED leverages its deep R&D capabilities in China to address unmet medical needs globally. The company maintains significant collaborations with major pharmaceutical players such as AstraZeneca and Takeda to accelerate the development and commercialization of its lead programs.